Rexulti, generically known as brexpiprazole, is an atypical antipsychotic medication primarily prescribed for the treatment of schizophrenia and as an adjunct therapy for major depressive disorder (MDD). Developed by Otsuka Pharmaceutical and Lundbeck, Rexulti has gained attention for its efficacy […]
